Galapagos Archives

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

biotech stock price euronext genmab argenx

News and Trends 25 May 2021

Delayed IPOs and Market Drops Batter Biotech Stocks

Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […]

May 25, 2021 - 6 minutesmins - By Jonathan Smith

News and Trends 4 Mar 2021

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in recent months. Yet the pair claim to be well capitalized to weather the storm and determined to do so together. The two companies forged an unusual blockbuster agreement in 2019, valued at around €4.5B ($5.1B), […]

March 4, 2021 - 4 minutesmins - By Victor Kotsev

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 5 Oct 2020

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

The recent EU and Japan approvals of the rheumatoid arthritis drug filgotinib contrast with the FDA’s rejection in August. What does this signal for Galapagos, Gilead, and other biotechs working in inflammatory disease? For Galapagos and Gilead, it’s been a rollercoaster few months. In August, the FDA decided against approving their drug filgotinib for treating […]

October 5, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 29 Oct 2019

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing eczema symptoms. The drug was being developed to treat the inflammatory skin condition atopic dermatitis, also known as eczema. It arose from a collaboration between […]

October 29, 2019 - 2 minutesmins - By Jonathan Smith

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

Expert Advice 8 Jun 2019

Why Sticking to Your Beliefs is Important for Biotech Success

Galapagos is an undeniable success story. Set up in 1999, it is now one of the largest and most successful biotechs in Europe. A key driving force behind the company is Onno van de Stolpe, its founder and CEO. After doing an internship at Biogen while at university, van de Stolpe knew he wanted to […]

June 8, 2019 - 11 minutesmins - By Helen Albert

Best in Biotech 2 Apr 2019

The 8 Best Biotech Companies in Europe’s History

We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and the development of the booming industry that biotech is today. Though the beginnings of the biotech industry are commonly traced back to the US, Europe has stepped up as a major contender and ally in […]

April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 23 Oct 2018

Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur

What does it take to be a successful biotech entrepreneur? I put this and other similar questions to Dinko Valerio, a highly experienced Dutch geneticist turned serial entrepreneur and investor. While there are many great scientists, it takes a certain something to be able to cross over into industry and build a profitable business. Dinko […]

October 23, 2018 - 8 minutesmins - By Helen Albert

News and Trends 20 Feb 2018

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody that could compete with the world’s best selling drug, Humira. The team announced details on positive results of a Phase I trial for treating atopic dermatitis […]

February 20, 2018 - 3 minutesmins - By Alexander Burik

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Galapagos

The Billion-Euro European Biotech Companies in 2022

Delayed IPOs and Market Drops Batter Biotech Stocks

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

A Year to Remember: The Biggest European Biotech News in 2020

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Gilead Pays Billions for Access to Galapagos’ Pipeline

Why Sticking to Your Beliefs is Important for Biotech Success

The 8 Best Biotech Companies in Europe’s History

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!